scholarly journals ADAPTED EVIDENCE-BASED CLINICAL GUIDELINES: BRONCHIAL ASTHMA (PART 3)

2021 ◽  
Vol 2021 (2) ◽  
pp. 5-20
Author(s):  
Yu. I. Feshchenko ◽  
◽  
L. O. Iashyna ◽  
D. M. Boiko ◽  
V. K. Gavrysiuk ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
Asthma Management ◽  
Global Strategy ◽  
Family Doctors ◽  
Treatment Regimens ◽  
New Approaches ◽  
Key Words Bronchial Asthma ◽  
Asthma Patients ◽  
Care Family ◽  
The Difference

C. Clinical guideline is the result of an agreed decision of experts, adopted on the basis of a thorough analysis of literature data, as well as recommendations of foreign guideline GINA: Global Strategy For Asthma Management And Prevention. Updated 2019. The document provides an updated definition of bronchial asthma (BA), gives new approaches to the classification and diagnosis of the disease, proposes modern treatment regimens based on the results of multicenter international clinical trials, which justifies the high evidence for such therapeutic tactics. New principles for the distribution of patients to phenotypes, which should be taken into account when choosing treatment regimens, are presented, algorithms for initial and maintenance therapy, and new approaches to the treatment of exacerbations of the disease are presented. In previous publications of the manual (Asthma and Allergy, 2020, № 2, № 3), an updated definition and pathogenetic mechanisms of BA were presented, new approaches to the classification and diagnosis of the disease were outlined, and the definition and assessment of asthma control were given. The principles of assessing the severity of asthma, as well as the difference between severe and uncontrolled asthma are considered. Standards for the treatment of asthma patients according symptoms control and minimize risk are presented. The basic principles of asthma management and alternative correction strategies of treatment are considered. The third part of the manual presents a stepwise approach to the correction of therapy, immunotherapy with allergens, vaccination, indications for referral to a specialist consultation. The guideline is addressed to doctors at all levels of medical care – family doctors, general practitioners, pulmonologists, allergists, cardiologists, rehabilitologists. Key words: bronchial asthma, pathogenesis, classification, diagnosis, therapy

scholarly journals Efektivitas Pemberian Oksigen Posisi Semi Fowler Dan Fowler Terhadap Perubahan Saturasi Pada Pasien Asma Bronkial Persisten Ringan

JKEP ◽  
2019 ◽  
Vol 4 (1) ◽  
pp. 31-43
Author(s):  
Syamsul Firdaus ◽  
Misbachul Munirul Ehwan ◽  
Agus Rachmadi
Keyword(s):  
Oxygen Saturation ◽  
Bronchial Asthma ◽  
Oxygen Therapy ◽  
Sampling Technique ◽  
T Test ◽  
Low Oxygen ◽  
Asthma Attack ◽  
Asthma Patients ◽  
The Difference ◽  
Persistent Bronchial Asthma

Mild persistent bronchial asthma is a chronic inflammatory airway that cause the low oxygen saturation value (91-95%). Administering oxygen therapy, setting the position of the semi fowler and fowler can reduce the risk of a decreased chest configuration. This research aims to assess the difference of effectiveness of administering oxygen at semi fowler with fowler position to the saturation changes in mild persistent bronchial asthma patients in Ratu Zalecha Martapura Hospital. This research method is quasy Experiment. The population research are all patients who experience mild persistent bronchial asthma attack, the sample of this research are 20 respondents with purposive sampling technique and analyzed with independent T test. The results is at semi fowler position the average of oxygen saturation before the treatment is 93.10%, after administering oxygen therapy with semi fowler position the average saturation is 98.00%. At the fowler position the average of oxygen saturation before the treatment is 92.60%, after administering oxygen therapy with fowler position the average saturation is 98.00%. The independent T-test result showed no difference of effectiveness of administering oxygen at semi fowler with fowler position to the saturation changes in mild persistent bronchial asthma patients,so teh patients can be given both positions.

scholarly journals CURRENT ISSUES OF BRONCHIAL ASTHMA 2021: WORLD ASTHMA DAY AND THE IMPACT OF THE COVID-19 PANDEMIC

2021 ◽  
Vol 2021 (2) ◽  
pp. 21-26
Author(s):  
G. L. Gumeniuk ◽  
◽  
V. I. Ignatieva ◽  
S. G. Opimakh
Keyword(s):  
Bronchial Asthma ◽  
Viral Entry ◽  
High Performance ◽  
Inhaled Corticosteroids ◽  
Inhaled Steroids ◽  
Key Words Bronchial Asthma ◽  
Asthma Patients ◽  
Transmembrane Serine Protease ◽  
The Impact

This year’s World Asthma Day has the theme “Uncovering Asthma Misconceptions”. This position calls for action and action to clarify common myths and misconceptions about asthma that prevent asthma sufferers from receiving optimal benefits from major success in treating the condition. According to GINA experts, the most common mistakes in the world about asthma are as follows: 1. Myth: asthma is a childhood disease; people “outgrow” it as they age. True: asthma can occur at any age. 2. Myth: Asthma is an infectious disease. Truth: asthma is not contagious disease. 3. Myth: People with asthma should not exercise. Truth: When asthma is well controlled, individuals with asthma can exercise and achieve high performance in sports. 4. Myth: asthma can only be controlled with high doses of steroids. Truth: Most often, asthma is controlled with low doses of inhaled steroids. To a large extent, these theses refer to one of the most important challenges of our time — the management of patients with bronchial asthma in the context of the COVID-19 pandemic. Patients with asthma have a lower susceptibility to COVID-19, a less severe course, and a lower risk of hospitalizations due to COVID-19. Allergic asthma or its eosinophilic phenotype, intake of inhaled corticosteroids (ICS) have a positive effect on the course of the COVID-19 disease, since in such patients the lower expression level of ACE 2 receptors in the upper and lower respiratory tract, which are input receptors for SARS-CoV-2 virus. ICS such as budesonide or ciclesonide are capable of inhibiting the replication of genomic SARS-CoV-2 RNA due to the influence of viral endonuclease NSP15 and TMPRSS2 (transmembrane serine protease 2), a protease involved in viral entry into the cell. Some ICS (including budesonide) reduce or block SARS-CoV-2 replication in vitro. Experts from international asthma groups note that in the face of the COVID-19 pandemic, asthma patients should continue to take basic therapy, including corticosteroids. And in current studies, ICS budesonide in COVID-19 patients reduces the risk of hospitalization or emergency care by 91 % and significantly improves clinical recovery. Key words: bronchial asthma, COVID-19, inhaled corticosteroids, World Asthma Day.

scholarly journals Management of the Bronchial Asthma Patients at Practice of Family Doctors

2020 ◽  
Vol 8 (1) ◽  
pp. 45
Author(s):  
Yuriy Mostovoy ◽  
Anna Demchuk ◽  
Tetyana Konstantynovych
Keyword(s):  
Bronchial Asthma ◽  
Family Doctors ◽  
Asthma Patients

scholarly journals MULTISLICE COMPUTED TOMOGRAPHY TO MEASURE VISCERAL FAT AREA IN PATIENT WITH ASTHMA AND OBESITY

2018 ◽  
Vol 99 (5) ◽  
pp. 264-268
Author(s):  
N. S. Serova ◽  
N. V. Chichkova ◽  
A. A. Gasparyan ◽  
L. B. Kapanadze ◽  
V. V. Fomin
Keyword(s):  
Computed Tomography ◽  
Multislice Computed Tomography ◽  
Subcutaneous Fat ◽  
Asthma Management ◽  
Global Strategy ◽  
Response To Therapy ◽  
The Body ◽  
Obesity Prevalence ◽  
Visceral Fat Area ◽  
Asthma Patients

Asthma and obesity prevalence in population have increased over the last years. In the Global Strategy for Asthma Management and Prevention (GINA, 2017) the “asthma-obesity” phenotype is identified, it has certain clinical features, disease course and response to therapy. One of the hypotheses explaining the relationship between asthma and obesity is the systemic inflammation theory. The visceral adipose tissue (VAT) plays a key role in this hypothesis, it produces various adipokines, imbalance of which results in the state of mild inflammation. With that only the body mass index (BMI) is used to diagnose obesity in asthma patients, but BMI doesn’t take into account the amount of VAT in the body.The clinical case of a patient with asthma in combination with third degree of obesity is presented. Additionally the patient was given a multislice computed tomography to measure the visceral and subcutaneous fat areas, followed by an evaluation of the obtained data and a collation of the parameters with clinical and anthropometric characteristics.

MYCOPLASMA AND CHLAMYDIA AS ETHIOLOGICAL FACTORS OF BRONCHIAL ASTHMA IN TERMS OF ETHNOGENESIS

2013 ◽  
Vol 68 (7) ◽  
pp. 57-60
Author(s):  
O. A. Sharavii ◽  
S. V. Smirnova
Keyword(s):  
Immune Response ◽  
Chlamydia Trachomatis ◽  
Blood Serum ◽  
Bronchial Asthma ◽  
Mycoplasma Hominis ◽  
Acute Stage ◽  
Control Group ◽  
Clinical Markers ◽  
Chlamydophila Psittaci ◽  
Asthma Patients

 Aim. The study of the prevalence and clinical peculiarities of Mycoplasmosis and Chlamydiosis in patients with different pathogenic forms of bronchial asthma (BA) taking into account ethnicity of a patient. Subjects and Methods. The research covered 239 subjects – both the Europeoids and the Mongoloids in the city of Krasnoyarsk and the town of Kyzyl, all of them being BA patients of different stages, including acute stage and practically healthy. We had determined antigens Mycoplasma pneumoniae, Mycoplasma hominis, Chlamydophila pneumoniae, Chlamydophila psittaci and Chlamydia trachomatis in smears of mucosa of pharynx and antibodies to these antigens in peripheral blood serum. Results.  We found high frequency of Mycoplasmosis and Chlamydiosis in the inhabitants of Eastern Siberia, BA patients with different pathogenic forms as compared to control group. We had determined ethnic peculiarities of specific immune response: IgM to М. pneumoniae was revealed in the Europoids more frequently than in the Mongoloids, but IgM to С. pneumoniae and to C. trachomatis, C. trachomatis antigens had been revealed more often in the Mongoloids than in the Europoids. We accepted as clinical equivalents of Mycoplasmosis and Chlamydiosis diagnostics the following signs: temperature around 37C (subfebrile temperature), non-intensive but stable coughing with scanty mucous and muco-purulent sputum, dyspnea of mixed character. Conclusions. Mycoplasma and Chlamydia are meaningful etiologic factors of bronchial asthma. We have found the peculiarities of immune response depending on ethnicity of a patient (ethnic belonging). Clinical markers of Mycoplasmosis and Chlamydiosis should be taken into account in bronchial asthma in order to provide diagnostics timely as well as eradication of infection agents. Because of insufficient knowledge of problem of bronchial asthma related to contamination with Мycoplasma and Chlamydia we put the goal to study the frequency of Mycoplasmosis and Chlamydiosis occurrence in bronchial asthma patients and determine the characteristics clinical course of diseases. We defined antigens Мycoplasma pneumoniae, Мycoplasma hominis, Chlamydophila pneumoniaе, Chlamydophila psittaci, Chlamydia trachomatis in smears of oropharynx mucosa and antibodies to them in blood serum. 

scholarly journals Classification of non-acute bronchial asthma according to allergy and eosinophil characteristics: a retrospective study

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Yi Jiang ◽  
Ruoli An ◽  
Li Cheng ◽  
Qianru Yue ◽  
Hanwei Zhang ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Lung Function ◽  
Allergic Asthma ◽  
Asthma Management ◽  
Effective Management ◽  
Sputum Cytology ◽  
Eosinophilic Asthma ◽  
Asthma Patients ◽  
Medical University

Abstract Background Investigating the endotypes of the different asthma phenotypes would help disease monitoring, prognosis determination, and improving asthma management standardization. This study aimed to classify asthma into four endotypes according to the allergic and eosinophilic characteristics and explore the phenotypes (clinical characteristics, pulmonary functions, and fractional expired nitric oxide (FeNO)) of each endotype. Methods This retrospective study included non-acute asthma patients treated at the First Hospital of Shanxi Medical University (05/2016–01/2018). The patients were classified into the eosinophilic allergic, eosinophilic non-allergic, non-eosinophilic allergic, and non-eosinophilic non-allergic asthma endotypes. Serum sIgE, lung function, FeNO, and induced sputum cytology were tested and compared among groups. Results Of the 171 included patients, 22 had eosinophilic allergic asthma, 17 had eosinophilic non-allergic asthma, 66 had non-eosinophilic allergic asthma, and 66 had non-eosinophilic non-allergic asthma. Lung function measurements (FEV1%, FEF25%, FEF50%, FEF75%, and FEF25–75%) showed that airway dysfunction was worse in eosinophilic non-allergic asthma than in the other three endotypes (all P < 0.001). In allergic asthma patients, eosinophilic asthma had worse airway dysfunction than non-eosinophilic asthma (all P < 0.05). Similar results were found in non-allergic asthma (all P < 0.01). The FeNO levels in eosinophilic allergic asthma were higher than in eosinophilic non-allergic and non-eosinophilic non-allergic asthma (both P = 0.001). Conclusions FeNO can objectively reflect eosinophilic airway inflammation in asthma. Endotypic classification of asthma patients regarding the allergic and eosinophilic characteristics is conducive to the effective management of patients with asthma.

Comparison between Compliance of Fluticasone Propionate Diskhaler and of Fluticasone Propionate Diskus in Adult Bronchial Asthma Patients

Respiration ◽  
2006 ◽  
Vol 73 (5) ◽  
pp. 680-684 ◽  
Author(s):  
Takashi Hasegawa ◽  
Eiichi Suzuki ◽  
Katsuya Fujimori ◽  
Takuro Sakagami ◽  
Shinichi Toyabe ◽  
...  
Keyword(s):  
Fluticasone Propionate ◽  
Bronchial Asthma ◽  
Asthma Patients

Demystifying the Belt and Road Initiative: China’s domestic and non-strategic policy?

2021 ◽  
pp. 205789112110388
Author(s):  
Yuan Jiang
Keyword(s):  
Global Strategy ◽  
Chinese Economy ◽  
Chinese Government ◽  
Belt And Road Initiative ◽  
Xi Jinping ◽  
One Belt One Road ◽  
Belt And Road ◽  
Strategic Policy ◽  
The Difference ◽  
The Belt And Road

The Belt and Road Initiative (BRI) is a central policy of the Chinese government. The initiative is directly associated with President Xi Jinping, who first put forward the BRI in Kazakhstan and Indonesia in 2013, initially as One Belt One Road. Different from repetitive literature that concludes the BRI as China's global strategy, this article makes a contribution to argue that the BRI is China's domestic and non-strategic policy. To justify this argument, this article analyses how the BRI has been embedded into aspects of Chinese domestic policy by revealing its nexuses with Chinese domestic economy, politics and ideology. To deepen the understanding of the BRI's connection with the Chinese economy, this article explores the link between the BRI and China's supply-side structural reform. Meanwhile, this research demystifies the BRI as a global strategy and the difference between joining and rejecting the BRI to prove the BRI's non-strategic essence. In the end, this article discusses the BRI's far-reaching geopolitical influence.

Sign in / Sign up

Export Citation Format

Share Document